RAINBOW - Rainbow Child.
📢 Recent Corporate Announcements
Rainbow Children's Medicare Limited has scheduled two days of in-person group meetings with institutional investors in Mumbai. On February 25, 2026, the management will attend the 17th Enterprising India Global Investors’ Conference organized by IIFL Capital. This will be followed by participation in the Kotak Securities flagship conference, 'Chasing Growth 2026', on February 26, 2026. These meetings are part of the company's regular engagement with the investment community to discuss business performance and outlook.
- Participation in the 17th Enterprising India Global Investors’ Conference on February 25, 2026
- Attendance at the Kotak Securities 'Chasing Growth 2026' flagship conference on February 26, 2026
- Both events are full-day, in-person group meetings scheduled to take place in Mumbai
- The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions
Rainbow Children's Medicare reported a 12% YoY revenue growth to ₹445.4 crores for Q3 FY26, while PAT grew 7% to ₹73.9 crores. The company is transitioning from a heavy expansion phase to an execution phase, having recently commissioned hospitals in Rajahmundry and Electronic City. Despite steady operational growth in deliveries (up 16%) and IP discharges (up 9%), occupancy remained at 47.2% due to muted seasonal illnesses. The appointment of Abrarali Dalal as CEO and a strong cash reserve of ₹579 crores position the company for future organic and inorganic growth.
- Revenue grew 12% YoY to ₹445.4 crores; EBITDA increased 9% to ₹147 crores with a 33% margin.
- Deliveries saw an impressive 16% YoY growth, while IP discharges and OP volumes rose by 9% and 18% respectively.
- Maintains a robust balance sheet with ₹579 crores in cash to fund future CAPEX and M&A through internal accruals.
- Commissioned 100-bed Rajahmundry and 90-bed Electronic City units; 60-bed Hennur unit awaiting final approvals.
- Successful first pediatric liver transplant in Bengaluru hub, achieving a 94% survival rate across the network.
Rainbow Children's Medicare Limited has made the audio recording of its Q3 and 9M FY26 earnings conference call available to the public. The call was conducted on January 29, 2026, following the release of the company's financial results. This filing is a standard regulatory requirement under SEBI Listing Regulations to ensure transparency for all shareholders. Investors can access the recording via the company's investor relations portal to hear management's detailed commentary on the quarter's performance.
- Audio recording of the Q3 & 9M FY26 investor conference call is now accessible.
- The call took place on January 29, 2026, involving discussions with analysts and institutional investors.
- Disclosure submitted in compliance with Regulation 30 and 46(2) of SEBI Listing Regulations.
- The recording link is hosted on the company's official website for stakeholder review.
Rainbow Children's Medicare reported a robust 21.2% YoY growth in operating revenue for Q3 FY26, reaching ₹4,057 million. The company witnessed strong volume growth with out-patient consultations increasing by 18% and in-patient discharges by 9%. Expansion remains a key theme, with three new hospitals operationalized in Warangal, Guwahati, and Rajahmundry during the fiscal year. While EBITDA grew 14.3% to ₹1,313 million, overall occupancy moderated to 47.2% due to the significant addition of new capacity beds.
- Operating Revenue increased 21.2% YoY to ₹4,057 million in Q3 FY26.
- EBITDA stood at ₹1,313 million, up 14.3% YoY, with a margin of 32.4%.
- Out-patient consultations grew 18% YoY to 4,17,342; In-patient discharges rose 9% to 27,977.
- ARPOB (Average Revenue Per Occupied Bed) improved by 9% YoY to ₹58,362.
- Total capacity beds reached 2,285 following the addition of hospitals in Warangal, Guwahati, and Rajahmundry.
Rainbow Children’s Medicare reported a steady Q3 FY26 with revenue growing 11.9% YoY to ₹4,454 Mn and PAT increasing 7.2% to ₹739 Mn. While operational capacity expanded by 18% to 2,285 beds, occupancy rates dipped to 47.19% from 53.20% YoY due to the rapid addition of new units in Rajahmundry and Bengaluru. The company has largely completed its current expansion cycle and is now focusing on operational excellence and ramping up occupancy in new facilities. A strong cash position of ₹5,792 Mn supports future growth and ongoing projects in Gurugram and Pune without external debt.
- Revenue grew 11.9% YoY to ₹4,454 Mn, while EBITDA margins remained healthy at 33.0%.
- Operational beds increased by 15% to 1,758, though occupancy fell 601 bps to 47.19% due to new capacity additions.
- ARPOB (Average Revenue Per Occupied Bed) improved by 9% YoY to ₹58,362.
- Commissioned two new hospitals in Rajahmundry (100 beds) and Electronic City, Bengaluru (90 beds).
- Maintains a robust cash and investment balance of ₹5,792 Mn as of December 31, 2025.
Rainbow Children's Medicare Limited has announced the grant of 1,00,000 stock options to eligible employees under its Employee Stock Option Scheme 2025. Each option is exercisable into one equity share of face value ₹10 at a discount of up to 20% on the market price as of January 27, 2026. The company also noted the cancellation of 6,430 previously granted options from July 2025 due to employee exits. This move is part of the company's long-term strategy to retain and incentivize talent.
- Grant of 1,00,000 stock options convertible into an equal number of equity shares
- Exercise price set at a maximum discount of 20% on the NSE closing price of Jan 27, 2026
- Vesting period ranges from a minimum of 1 year to a maximum of 10 years from the grant date
- Vested options must be exercised within a maximum of 2 years from the date of vesting
- Cancellation of 6,430 stock options previously granted in July 2025 due to employee attrition
Rainbow Children's Medicare reported a standalone revenue of ₹3,943.52 million for Q3 FY26, a 3.4% increase over ₹3,815.65 million in Q3 FY25. Standalone Profit After Tax (PAT) declined slightly by 1.7% YoY to ₹658.24 million, down from ₹669.75 million. Sequentially, the performance was lower than Q2 FY26, where revenue was ₹4,084.96 million and PAT was ₹731.67 million. The board also confirmed the appointment of Mr. Abrarali Dalal as CEO starting January 2026.
- Standalone Revenue from operations grew 3.35% YoY to ₹3,943.52 million
- Standalone Profit After Tax (PAT) decreased by 1.7% YoY to ₹658.24 million
- Total expenses rose to ₹3,166.74 million from ₹3,023.00 million in the previous year's quarter
- Basic EPS for the quarter stood at ₹6.48 compared to ₹6.60 in Q3 FY25
- Mr. Abrarali Dalal officially took charge as the Chief Executive Officer (CEO) on January 20, 2026
Rainbow Children’s Medicare Limited (RCML) has inaugurated a new 90-bed spoke hospital in Electronic City, Bengaluru, increasing its total capacity to approximately 2,375 beds. The project, costing approximately ₹55 crore, was funded entirely through internal accruals, demonstrating strong cash flow management. This facility marks the company's fifth hospital in Bengaluru and will operate under the hub-and-spoke model linked to the Marathahalli hub. This expansion targets a high-growth corridor with a young population, enhancing the company's footprint in a key focus market.
- New 90-bed spoke hospital launched in Electronic City, Bengaluru, increasing total capacity to ~2,375 beds.
- Total project investment of approximately ₹55 crore financed through internal accruals.
- Strengthens the hub-and-spoke model in Bengaluru, serving as a spoke to the Marathahalli hub.
- Company occupancy stood at 46.3% in Q2 FY 2025-26 prior to this addition.
- The facility offers comprehensive pediatric and perinatal services, including neonatal and pediatric intensive care.
Rainbow Children's Medicare Limited has scheduled its earnings conference call for the third quarter of FY26 on January 29, 2026, at 10:00 AM IST. The management team, including the Chairman & MD and the Group CEO, will discuss the company's financial and operating performance. This call provides a platform for institutional investors and analysts to gain clarity on the company's business strategy and future outlook. The event is hosted by IIFL and includes international dial-in facilities for global participants.
- Earnings conference call for Q3 FY26 is set for Thursday, January 29, 2026, at 10:00 AM IST.
- Management participants include Dr. Ramesh Kancharla (Chairman and MD) and Mr. Abrar Ali Dalal (Group CEO).
- Primary India dial-in numbers are +91 22 6280 1259 and +91 22 7115 8160.
- International toll-free numbers are available for the USA, UK, Singapore, and Hong Kong.
- The discussion will focus on financial performance, business strategy, and the outlook post-Q3 results.
Rainbow Children's Medicare Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by KFIN Technologies Limited, confirms that no shares were dematerialized or rematerialized during the quarter ended December 31, 2025. This is a standard procedural filing required by the stock exchanges to maintain updated shareholding records. The announcement indicates full compliance with depository regulations for the period.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Registrar KFIN Technologies confirms NIL dematerialization or rematerialization requests
- Filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- The report covers interactions with both NSDL and CDSL depositories
Rainbow Children's Medicare Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The window will remain closed until 48 hours after the declaration of the financial results for the quarter and nine months ending December 31, 2025. This is a standard regulatory procedure for listed companies in India to prevent insider trading during the sensitive period before earnings releases.
- Trading window for company securities to close effective January 1, 2026.
- Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
- Trading window will reopen 48 hours after the official announcement of financial results.
- The notice is issued in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Rainbow Childrens Medicare Limited has announced meetings with analysts and institutional investors. The meetings are scheduled for December 9, 2025, and December 10, 2025, in Mumbai. These meetings are organized by Prabhudas Liladhar. The company has stated that no UPSI (Unpublished Price Sensitive Information) will be shared during these engagements.
- Analyst/Institutional Investor Meeting on December 9, 2025
- Analyst/Institutional Investor Meeting on December 10, 2025
- Meetings organized by Prabhudas Liladhar
Financial Performance
Revenue Growth by Segment
Consolidated total income grew by 17.46% YoY to INR 15,668.74 million in FY 2024-25, driven by a 12.15% increase in In-patient volumes (98,395) and an 11.72% rise in Out-patient volumes (1,426,733). Pediatric and perinatal services remain the core revenue contributors.
Geographic Revenue Split
Hyderabad remains the primary revenue driver, though concentration is reducing as the company expands. New growth is being targeted in the National Capital Region (NCR) with two land parcels in Gurugram (Sector-44 and Sector-56) and recent acquisitions in Guwahati and Warangal.
Profitability Margins
Net Profit Margin stood at 16.11% in FY 2024-25, a slight compression from 16.83% in FY 2023-24. This was due to a 19.02% increase in total expenses, particularly employee benefits and professional fees, which outpaced revenue growth.
EBITDA Margin
EBITDA margin was 32.32% in FY 2024-25 (INR 4,898.88 million), down from 33.07% YoY. The 14.22% growth in absolute EBITDA was supported by optimized cost structures despite rising operational costs.
Capital Expenditure
The company has a capex commitment of INR 350-450 crore over the next 12 months as of June 2025. Significant investments are directed toward the NCR expansion and upgrading medical equipment to maintain a competitive edge in advanced treatments.
Credit Rating & Borrowing
The company maintains a strong liquidity position with cash and investments of INR 735.5 crore as of June 30, 2025. ICRA notes a strong financial profile with the ability to raise debt at short notice if required, though current growth is largely funded through internal accruals.
Operational Drivers
Raw Materials
Key cost drivers include Professional Fees to Doctors (representing a 20.84% increase in cost) and Employee Benefit Expenses (representing a 17.14% increase). Medical consumables and lab investigations also constitute significant operational outlays.
Import Sources
Not specifically disclosed, but medical equipment and specialized consumables are typically sourced from global medical technology hubs and domestic suppliers in India.
Capacity Expansion
Current workforce includes 3,972 permanent employees. Expansion includes groundbreaking at two sites in Gurugram and the integration of newly acquired units in Guwahati and Warangal to increase bed capacity.
Raw Material Costs
Total expenses rose 19.02% to INR 12,368.73 million. Professional fees to doctors and employee benefits are the largest components, rising 20.84% and 17.14% respectively, reflecting the high cost of specialized medical talent.
Manufacturing Efficiency
Occupancy rates improved to 50.53% in FY 2024-25 from 47.91% YoY. Average Length of Stay (ALOS) increased by 7.55% to 2.85 days, while ARPOB decreased by 3.39% to INR 53,962.
Logistics & Distribution
Not disclosed as a percentage of revenue; logistics primarily involve the movement of medical supplies and emergency ambulance services.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved by stabilizing mature units at 8-10% growth while driving 25% growth in newer units. The strategy includes completing NCR expansions by FY26, integrating M&A assets like Guwahati and Warangal, and leveraging high-yield mutual fund rebalancing (INR 171.21 million increase in income) to fund operations.
Products & Services
Pediatric super-specialty care (cardiology, nephrology, oncology, gastroenterology), obstetrics, gynecology, tertiary and quaternary care, and perinatal services.
Brand Portfolio
Rainbow Children's Hospital, Rainbow Children's Medicare Limited.
New Products/Services
Expansion into international patient services and deepening super-specialty offerings in cardio and oncology are expected to drive higher ARPOB.
Market Expansion
Aggressive expansion into North India (NCR) and strengthening presence in Chennai and Bengaluru to reduce geographic concentration in Hyderabad.
Market Share & Ranking
The company is a leading player in specialized pediatric care in South India and is currently scaling to become a national player.
External Factors
Industry Trends
The industry is shifting toward specialized 'single-specialty' hospitals. Rainbow is positioned as a pure-play pediatric and maternity provider, which typically commands higher margins (86-87% gross margins) compared to the 73-74% industry average for multi-specialty hospitals.
Competitive Landscape
Faces stiff competition from established multidisciplinary hospitals in Chennai, Delhi, and Bengaluru where Rainbow is a newer entrant with lower brand recognition.
Competitive Moat
Moat is built on a specialized clinical talent pool and a 'Great Place to Work' culture (certified 5 times), which helps in retaining doctors in a highly competitive market. The focus on high-complexity pediatric cases creates high switching costs and brand loyalty.
Macro Economic Sensitivity
Healthcare demand is relatively inelastic, but high inflation can increase staff costs and medical consumable prices, impacting the 32.32% EBITDA margin.
Consumer Behavior
Increasing preference for specialized pediatric care over general hospitals and rising demand for high-end perinatal services among urban populations.
Geopolitical Risks
Minimal direct impact, though global supply chain disruptions can delay the procurement of advanced medical machinery for the Gurugram expansion.
Regulatory & Governance
Industry Regulations
Subject to Clinical Establishments Act, biomedical waste management rules, and potential government-mandated price caps on essential treatments and surgeries.
Environmental Compliance
Compliant with waste management guidelines; focus on reducing water consumption and identifying health and safety hazards.
Taxation Policy Impact
Effective tax rate is approximately 25.99% (INR 857.74 million tax on INR 3,300.01 million PBT).
Legal Contingencies
Exposure to medical litigation and high compliance standards; however, no specific high-value pending court cases were quantified in the provided text.
Risk Analysis
Key Uncertainties
Rapid technological advancement leads to swift equipment obsolescence, requiring frequent capital outlays. Failure to attract/retain top-tier medical talent could impact patient footfalls and revenue by 15-20%.
Geographic Concentration Risk
High dependence on the Hyderabad market for a significant portion of earnings, though this is being mitigated by the NCR and South India expansion.
Third Party Dependencies
Dependency on key consultants and doctors; the loss of key medical personnel is a critical risk to operational continuity.
Technology Obsolescence Risk
High risk due to the capital-intensive nature of healthcare; the company must constantly reinvest in state-of-the-art infrastructure to remain competitive.
Credit & Counterparty Risk
Trade receivables turnover is 20.52 days, indicating healthy collections and low credit risk from insurance providers and TPA partners.